MDC1 Antibody from MYBIOSOURCE INC.
Search, find, compare suppliers for anti-MDC1 antibody, protein, ELISA kits.
| Edit | |
|---|---|
| Antigenic Specificity | MDC1 |
| Clone | [P2B11] |
| Host Species | Mouse |
| Reactive Species | human, mouse, bovine, chimpanzee |
| Isotype | IgG1 |
| Format | APC-Cy7 conjugate |
| Size | 0.1 mg |
| Concentration | 1 mg/ml |
| Applications | Western Blot (WB), Immunocytochemistry (ICC), Immunofluorescence (IF) |
| Reviews / Ratings | If you have used this antibody, please help fellow researchers by submitting reviews to pAbmAbs and antYbuddY. |
| Description | Detects ~184 kDa. This antibody recognizes MDC1 at and around the N-terminus. MDC1, mediator of DNA damage checkpoint protein 1, plays a role in checkpoint mediated cell cycle arrest in response to DNA damage, within S phase and G2/M. It is also thought to act as a scaffold protein during recruitment of DNA repair and signal transduction proteins to discrete foci of DNA damage that are marked by phosphorylation of histone H2A.X on S139. |
| Immunogen | Immunogen: GST-tagged recombinant protein corresponding to mouse MDC1 at and around the N-terminus |
| Other Names | [Mouse Mouse MDC1 IgG1; MDC1 : APC/Cy7; Nuclear factor with BRCT domains1; mediator of DNA damage checkpoint 1] |
| Gene, Accession # | [MDC1], Gene ID: 240087, NCBI: NP_001010833.2, UniProt: Q5PSV9 |
| Catalog # | MBS8002560 |
| Price | $495 |
| Order / More Info | MDC1 Antibody from MYBIOSOURCE INC. |
| Product Specific References | 1. Lou Z., et al. (2004) J Biol Chem. 279(45): 46359-46362. 2. Luo K., Yuan J, Lou Z. (2011) J Biol Chem. 286(32): 28192-28199. 3. Strauss C., Halevy T., Macarov M., Argaman L., and Goldbery M. (2011) DNA Repair (Amst.). 10(8): 806-814. 4. Wilson K.A., et al. (2011) Mol Cancer Res. 9(6): 766-781. |
MYBIOSOURCE INC.
MYBIOSOURCE INC.
P.O. Box 153308
San Diego CA 92195-3308
P: 1.858.633.0165
P: 1.888.MBS.0165 (1.888.627.0165) (US & Canada)
F: 1.858.633.0166
sales@mybiosource.com
http://www.MyBioSource.com
Profile of MYBIOSOURCE INC.
Return to Antibodies